GPCR
Structure Therapeutics Inc.
Next earnings Aug 4, 2026 (after close) · consensus $-0.40 EPS
Last earnings -4.1% on 2026-05-07
$49.71
▲ +3.03%$49.71▲ +124.93%
over 1Y
L $16.20EODHDH $93.79
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.0%
1W+9.2%
1M+25.7%
3M+8.3%
YTD-27.0%
1Y+124.9%
Hold
Conviction
Horizon
Long (>12mo)
Street · 24 analysts
Buy
Pre-revenue GLP-1 oral biotech with $800M cash and a credible obesity pipeline, but binary clinical risk caps conviction.
Cash & equivalents $800M · FY2025
Structure Therapeutics is a clinical-stage biopharma with zero product revenue and widening losses (-$141M in FY2025 vs -$123M in FY2024, per the 10-K's own recap of '$141.2 million, $122.5 million and $89.6 million'). The investment case is entirely about the pipeline: aleniglipron (GSBR-1290), an oral small-molecule GLP-1R agonist 'currently in five ongoing clinical studies for the treatment of obesity,' plus two amylin candidates (ACCG-2671 in Phase 1 and ACCG-3535) and preclinical GIP/glucagon programs. The MD&A explicitly frames oral small molecules as 'potentially differentiated efficacy and safety and... more scalable to meet global demand' versus injectable peptides — the bull case in one line, if the data lands.
Financials · annual, by fiscal year
| Line item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$52.6M | -$103M | -$158M | -$177M |
| Net income | -$51.3M | -$89.6M | -$123M | -$141M |
| Diluted EPS | -$5.51 | -$0.81 | -$0.78 | -$0.80 |
| Net margin | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$9.77B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-1.3%
FCF yield-2.1%
Quality & risk
ROIC (est.)-9.2%
Free cash flow-$226M
Total debt—
Net cash$800M
Piotroski F-Score2/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+23.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has been improving.
- 8-K Shareholder vote2026-06-18
Annual meeting vote results disclosed; routine governance, no operational impact
- 8-K Material agreement2026-05-07
Q1 2026 results: continued R&D burn against ~$800M cash runway
- 10-Q Quarterly report2026-05-07
Q1 2026 results: continued R&D burn against ~$800M cash runway
- DEF 14A Proxy statement2026-04-23
Proxy for 2026 annual meeting; routine governance and comp disclosure
- 8-K Officer / director change2026-04-15
Executive officer change announced alongside Reg FD disclosure
- 8-K Reg FD disclosure2026-03-16
Reg FD/other disclosure issued, likely clinical or conference update
- 8-K Earnings results2026-02-26
FY25 loss widened to $141M; R&D doubled to $225M; cash jumped to $800M
- 10-K Annual report2026-02-26
FY25 loss widened to $141M; R&D doubled to $225M; cash jumped to $800M
- 8-K Material agreement2026-01-05
Entered a new material agreement, likely collaboration or supply deal
Recent filings
all on EDGAR ↗144Filing2026-06-25open ↗4Period ending 2026-06-172026-06-18open ↗4Period ending 2026-06-172026-06-18open ↗4Period ending 2026-06-172026-06-18open ↗4Period ending 2026-06-172026-06-18open ↗4Period ending 2026-06-172026-06-18open ↗4Period ending 2026-06-172026-06-18open ↗8-KPeriod ending 2026-06-172026-06-18open ↗10-QPeriod ending 2026-03-312026-05-07open ↗8-KPeriod ending 2026-05-072026-05-07open ↗424B5Filing2026-05-07open ↗ARSPeriod ending 2025-12-312026-04-23open ↗
Frequently asked
- Is Structure Therapeutics Inc. (GPCR) a buy?
- GPCR currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Pre-revenue GLP-1 oral biotech with $800M cash and a credible obesity pipeline, but binary clinical risk caps conviction.
- What is Structure Therapeutics Inc.'s quality score?
- GPCR scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001888886, latest 10-Q filed 2026-05-07) · EODHD · analysis by claude-code · as of 6/25/2026, 1:43:30 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.